Skip to content

Trial Summary

Three versus five years of adjuvant imatinib as treatment of patients with operable GIST with a high risk for recurrence: A randomised phase III multicenter study.



ACTRN/NCT /ethics:


Scientific title:

Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST

Sponsor / Cooperative group:

Heikki Joensuu

Trial & Patient Characteristics

Cancer TypeStomach & Oesophageal
Trial TypeTreatment
PhasePhase III
Age Range18 years to 100 years
Tumour Stream Gastrointestinal stromal tumor
Cancer StageEarly\In Situ
Anticipated Start Date2015-05-01
Anticipated End Date2028-05-01

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorStella Papacharissiou
Phone08 8222 6140
Principal InvestigatorProfessor Tim Price
Recruitment StatusRecruiting